2016
DOI: 10.6061/clinics/2016(01)08
|View full text |Cite
|
Sign up to set email alerts
|

Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control

Abstract: The purpose of this study was to evaluate the therapeutic options for diabetes treatment and their potential side effects, in addition to analyzing the risks and benefits of tight glycemic control in patients with diabetic kidney disease. For this review, a search was performed using several pre-defined keyword combinations and their equivalents: “diabetes kidney disease” and “renal failure” in combination with “diabetes treatment” and “oral antidiabetic drugs” or “oral hypoglycemic agents.” The search was per… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
46
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 52 publications
(46 citation statements)
references
References 69 publications
(81 reference statements)
0
46
0
Order By: Relevance
“…The main incretins in humans are GLP‐1 and glucose‐dependent insulinotropic polypeptide (GIP), which are secreted by the intestines after every meal. GLP‐1 receptor agonists then, work by the stimulation of GLP‐1 receptors, enhancing insulin secretion, appetite suppression, delaying gastric emptying, and inhibiting glucagon release from the pancreas . Current clinically used GLP‐1 RAs are resistant to Dipeptidyl Peptidase 4 (DPP4) cleavage and are generally long‐acting drugs, reducing HbA1C with a variability between 1.3% and 1.9% .…”
Section: Insulin Secretagoguesmentioning
confidence: 99%
See 2 more Smart Citations
“…The main incretins in humans are GLP‐1 and glucose‐dependent insulinotropic polypeptide (GIP), which are secreted by the intestines after every meal. GLP‐1 receptor agonists then, work by the stimulation of GLP‐1 receptors, enhancing insulin secretion, appetite suppression, delaying gastric emptying, and inhibiting glucagon release from the pancreas . Current clinically used GLP‐1 RAs are resistant to Dipeptidyl Peptidase 4 (DPP4) cleavage and are generally long‐acting drugs, reducing HbA1C with a variability between 1.3% and 1.9% .…”
Section: Insulin Secretagoguesmentioning
confidence: 99%
“…In fact, insulin clearance is highly dependent on GFR, and dose adjustment is necessary. Up to 50% reduction of total daily dose is recommended when eGFR falls between 10 and 50 mL/min/1.73 m 2 , and 75% reduction is indicated for eGFR below 15 mL/min/1.73 m 2 …”
Section: Insulinmentioning
confidence: 99%
See 1 more Smart Citation
“…Diabetes mellitus is an underlying cause of chronic kidney disease [48] . It develops certain degree of damage and lead to abnormal kidney function.…”
Section: ++mentioning
confidence: 99%
“…Glycemic control in patients with chronic kidney disease (CKD) adds another layer of complexity. Diabetes is the leading cause of CKD and a major public health issue worldwide. Approximately 25% of type 2 diabetes mellitus patients in Japan have renal impairment (RI) classified as moderate‐to‐severe CKD (glomerular filtration rate <60 mL/min/1.73 m 2 ).…”
Section: Introductionmentioning
confidence: 99%